Privia Health initiated with a Buy at UBS

UBS analyst Andrew Mok initiated coverage of Privia Health with a Buy rating and $30 price target. The company offers investors a "uniquely differentiated" primary care model that generates "resilient" earnings and cash flow from fee-based practice collections and elements of risk-taking from its high-performing ACOs, the analyst tells investors in a research note. Mok adds that he is positive on Privia’s position as a "well-capitalized, defensive, and capital-light" growth name.